Scott A. Gangloff Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Scott Gangloff AKRO stock SEC Form 4 insiders trading

Scott has made over 1 trades of the Akero Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Scott exercised 115,942 units of AKRO stock worth 2,970,434$ on 9 November 2016.

The largest trade Scott's ever made was exercising 115,942 units of Akero Therapeutics Inc stock on 9 November 2016 worth over 2,970,434$. On average, Scott trades about 38,647 units every 0 days since 2016. As of 9 November 2016 Scott still owns at least 115,942 units of Akero Therapeutics Inc stock.

You can see the complete history of Scott Gangloff stock trades at the bottom of the page.

What's Scott Gangloff's mailing address?

Scott's mailing address filed with the SEC is 7 Clarke Dr, Cranbury, NJ 08512, USA.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over 146,260,704$ worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth 104,250,550$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Trust Blue Horizon Enterpri...、G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,642,344$. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth 133,600$.

What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Cheng,
  President, Chief Executive Officer, Director
• William White,
  Chief Financial Officer, Executive Vice President and Head of Corporate Development
• Timothy Rolph,
  Co-Founder, Chief Scientific Officer
• Jonathan Young,
  Co-Founder, Chief Operating Officer, Executive Vice President
• Dr. Andrew Cheng,
  Pres, CEO & Director
• Dr. Timothy Rolph,
  Co-Founder & Chief Scientific Officer
• Dr. Jonathan M. Young,
  Co-Founder, Exec. VP, COO & Sec.
• William R. White J.D.,
  Exec. VP, CFO, Treasurer & Head of Corp. Devel.
• Mark Iwicki,
  Independent Non-Executive Chairman of the Board
• Kevin Bitterman,
  Non-Executive Independent Director
• Seth Harrison,
  Non-Executive Independent Director
• Graham Walmsley,
  Non-Executive Independent Director
• Kitty Yale,
  Chief Development Officer
• Jane Henderson,
  Non-Executive Independent Director
• Tomas Heyman,
  Independent Director
• Kitty Yale,
  Exec. VP & Chief Devel. Officer
• John J. Schembri,
  VP of Fin. & Controller
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Trust Blue Horizon Enterpri...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Group, Llc Green Jeremy Red...,
  
• Global Strategic Fund Ii L....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Aaron Royston,
  Director
• Venture Capital Vi, L.P. Ve...,
  10% owner
• Life Science Ventures, L.P....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Venture Opportunity Fund I,...,
  10% owner
• Chou Judy,
  
• Catriona Yale,
  Chief Development Officer
• Yuan Xu,
  
• Scott A. Gangloff,
  Chief Technology Officer
• Patrick Lamy,
  Senior VP, Commercial Strategy